浙江中西医结合杂志
浙江中西醫結閤雜誌
절강중서의결합잡지
Zhejiang Journal of Integrated Traditional Chinese and Western Medicine
2015年
10期
915-917
,共3页
朱金霞%王锡英%吕伟旗%季晓珍
硃金霞%王錫英%呂偉旂%季曉珍
주금하%왕석영%려위기%계효진
2型糖尿病%格列齐特缓释片%黄连素
2型糖尿病%格列齊特緩釋片%黃連素
2형당뇨병%격렬제특완석편%황련소
type 2 diabetes mellitus%gliclazide%berberine
目的：观察格列齐特缓释片联合黄连素治疗2型糖尿病的疗效及安全性。方法将118例2型糖尿病患者随机分为治疗组和对照组。对照组给予糖尿病饮食及知识教育，合理饮食控制与适量运动，口服格列齐特缓释片30mg，1天1次；治疗组在对照组治疗基础上给予口服黄连素0.1g，1天3次；两组疗程均为12周。评价两组临床疗效、血糖指标、脂代谢水平、C肽、低血糖事件及其他不良反应发生情况。结果治疗组总有效率（81.4%比62.7%，P<0.05）、餐后C肽水平[（3.68±0.45）mmol/L比（3.30±0.35）mmol/L]显著高于对照组，低血糖事件发生率（10.2%比25.4%）、2hBG [（7.28±1.82）mmol/L比（8.12±2.37）mmol/L]、HbA1c[（6.38±1.04）%比（7.05±1.67）%]均显著低于对照组，差异有统计学意义（P<0.05）；两组治疗前后脂代谢水平、其他不良反应发生率比较，差异无统计学意义（P>0.05）。结论格列齐特缓释片联合黄连素治疗2型糖尿病，疗效显著，且安全性较好。
目的：觀察格列齊特緩釋片聯閤黃連素治療2型糖尿病的療效及安全性。方法將118例2型糖尿病患者隨機分為治療組和對照組。對照組給予糖尿病飲食及知識教育，閤理飲食控製與適量運動，口服格列齊特緩釋片30mg，1天1次；治療組在對照組治療基礎上給予口服黃連素0.1g，1天3次；兩組療程均為12週。評價兩組臨床療效、血糖指標、脂代謝水平、C肽、低血糖事件及其他不良反應髮生情況。結果治療組總有效率（81.4%比62.7%，P<0.05）、餐後C肽水平[（3.68±0.45）mmol/L比（3.30±0.35）mmol/L]顯著高于對照組，低血糖事件髮生率（10.2%比25.4%）、2hBG [（7.28±1.82）mmol/L比（8.12±2.37）mmol/L]、HbA1c[（6.38±1.04）%比（7.05±1.67）%]均顯著低于對照組，差異有統計學意義（P<0.05）；兩組治療前後脂代謝水平、其他不良反應髮生率比較，差異無統計學意義（P>0.05）。結論格列齊特緩釋片聯閤黃連素治療2型糖尿病，療效顯著，且安全性較好。
목적：관찰격렬제특완석편연합황련소치료2형당뇨병적료효급안전성。방법장118례2형당뇨병환자수궤분위치료조화대조조。대조조급여당뇨병음식급지식교육，합리음식공제여괄량운동，구복격렬제특완석편30mg，1천1차；치료조재대조조치료기출상급여구복황련소0.1g，1천3차；량조료정균위12주。평개량조림상료효、혈당지표、지대사수평、C태、저혈당사건급기타불량반응발생정황。결과치료조총유효솔（81.4%비62.7%，P<0.05）、찬후C태수평[（3.68±0.45）mmol/L비（3.30±0.35）mmol/L]현저고우대조조，저혈당사건발생솔（10.2%비25.4%）、2hBG [（7.28±1.82）mmol/L비（8.12±2.37）mmol/L]、HbA1c[（6.38±1.04）%비（7.05±1.67）%]균현저저우대조조，차이유통계학의의（P<0.05）；량조치료전후지대사수평、기타불량반응발생솔비교，차이무통계학의의（P>0.05）。결론격렬제특완석편연합황련소치료2형당뇨병，료효현저，차안전성교호。
Objective To investigate clinical efficacy and safety of gliclazide combined with berberine in the treatment of type 2 diabetes mellitus. Methods Hundred and eighteen patients with type 2 diabetes mellitus were randomly divided into treatment group(n=59) and control group(n=59). Control group was given knowledge of dia-betes mellitus and diet; they were taken gliclazide tablet(30mg, once a day) and was asked keeping reasonable di-et and exercise. Treatment group was additionally given berberine tablet 0.1g (three times per day) on the base of control group. Treatment course of 2 groups lasted for 12 weeks. Clinical efficacy was evaluated; glucose, lipidemia, C-peptide, the occurrence of glucopenia and other adverse drug reaction were determined in 2 groups. Results The total effective rate of diabetes mellitus in treatment group was significantly higher than in control group(81.4%vs 62.7%, P<0.05), while the occurrence of glucopenia(10.2% vs 25.4%), index of 2hBG(7.28±1.82mmol/L vs 8.12±2.37mmol/L), HbA1c(6.38%±1.04% vs 7.05%±1.67%) and postprandial C-peptide(3.68±0.45mmol/L vs 3.30±0.35mmol/L) in treatment group was significantly lower than those in control group (all P<0.05). No statistical dif-ference in lipidemia and the incidence of adverse drug reaction other than glucopenia was found between 2 groups (P>0.05). Conclusion Gliclazide combined with berberine is effective for type 2 diabetes mellitus with good safety.
